Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 214
- Registration Number
- NCT00095173
- Locations
- 🇨🇭
Local Institution, Lausanne, Switzerland
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 738
- Registration Number
- NCT00048581
- Locations
- 🇺🇸
Local Institution, Milwaukee, Wisconsin, United States
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1250
- Registration Number
- NCT00048568
- Locations
- 🇺🇸
Local Institution, Milwaukee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.